PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase receptor	Homo sapiens	134-146	
30539695-6	2019	Here we will discuss recent evidence that bridges the gap between basic research in the field of the PA system and the bedside of ischemic stroke patients, indicating that uPA and uPAR are potential targets for the development of therapeutic strategies to promote neurological recovery among ischemic stroke survivors.	Protactinium	101-103	plasminogen activator, urokinase receptor	Homo sapiens	180-184	
11376560-3	2001	Among the PA system factors, both the levels of uPAR and PAI-1 were significantly higher in larger tumors than in smaller ones, and were also significantly higher in tumors that invaded subserosa, serosa or adjacent organs than in mucosal, submucosal tumors or in tumors that invaded the muscle layer.	Protactinium	10-12	plasminogen activator, urokinase receptor	Homo sapiens	48-52	
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	160-163	
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	185-189	
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	160-163	
7611439-7	1995	Plasminogen activator inhibitor-1 (PAI-1) inhibited PA activity of preformed uPA/uPAR complexes and increased cycling of the receptor from the cell surface.	Protactinium	35-37	plasminogen activator, urokinase receptor	Homo sapiens	81-85	
20943061-5	2010	The expression of the components of the PA system, including uPA, its type-1 and type-2 inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), was examined by Western blot in fibroblasts from patients affected by limited and diffuse forms of SSc.	Protactinium	40-42	plasminogen activator, urokinase receptor	Homo sapiens	135-139	
12405290-7	2002	In the PA system, uPAR antigen levels were significantly higher in tumors with COX-2 expression than in tumors without (P = 0.0233).	Protactinium	7-9	plasminogen activator, urokinase receptor	Homo sapiens	18-22	
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase receptor	Homo sapiens	148-153